Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study
Authors' conclusion
The analysis indicates stability of RA-ILD in patients treated with JAKi. The tolerance profile of JAKi in this higher risk population did not reveal new safety signal.
Study context
- Population
- Patients with RA-ILD treated with JAKi in France, MAJIK-SFR registry (mean age 61±13 years; mean disease duration 16±10 years)26 women, 62%
- Participants
- 42 patients
- Outcome
- Course of RA-ILD on JAKi: HRCT, FVC and DLCO, acute exacerbations of ILD, respiratory infections and lung cancers
- Follow-up
- 6 months, 12 months and a median of 21 months postinclusion
Methodological detailsnational, multicentre, observational, registry-based (MAJIK-SFR)
- National
- Multicentre
- Observational
- Registry-based (MAJIK-SFR)
Main finding
As reported in the abstract
Course of RA-ILD on JAKi
Chest high-resolution CT (HRCT) lesions stable
69%
Progressive ILD
8 patients
19%
Observational data: associations, not effects.
Further findings
Chest HRCT ILD patterns
- Non-specific interstitial pneumonia
- 46%
- Usual interstitial pneumonia
- 43%
Deaths
- No deaths occurred
Safety
Respiratory tract infections
- Respiratory tract infections observed
- 16 (38%)
Acute exacerbation of ILD
- Acute regressive exacerbation of ILD
- 1
Lung cancer
- No lung cancer diagnosed
JAKi discontinuation
- JAKi discontinued
- 17
- Discontinued for inefficacy on joint involvement
- 8
- Discontinued for intolerance
- 5
Original publication
Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study. RMD Open. Published 6 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →